Table 3—

Long-term changes on sildenafil therapy by acute sildenafil response#

Baseline3 monthsp-value
Major acute effect group
 WHO class II/III/IV n2/30/33/31/1
 6MWD m310±18358±260.005
pa mmHg47±242±30.05
 CI L·min−1·m−22.0±0.12.5±0.20.001
 PVR dyn·s·cm−5916±66632±1120.002
Minor acute effect group+
 WHO class II/III/IV n1/25/62/30/0
 6MWD m301±21379±260.02
pa mmHg46±243±20.4
 CI L·min−1·m−22.3±0.12.7±0.20.005
 PVR dyn·s·cm−5770±61624±820.03
  • Data are presented as mean±sem, unless otherwise stated. WHO: World Health Organization; 6MWD: 6-min walking distance; pa: mean pulmonary arterial pressure; CI: cardiac index; PVR: pulmonary vascular resistance. #: in a subset of 67 patients; : n = 35; +: n = 32.